Roivant Sciences (NASDAQ:ROIV) Announces Quarterly Earnings Results, Beats Estimates By $0.57 EPS

Posted by Geri Gentry on May 22nd, 2026

Roivant Sciences (NASDAQ:ROIV – Get Free Report) posted its earnings results on Wednesday. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.57, FiscalAI reports. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.The firm had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. During the same quarter in the prior year, the company earned ($0.29) EPS.

Here are the key takeaways from Roivant Sciences’ conference call:

Roivant reported encouraging preliminary open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, with about 73% ACR20, over 50% ACR50, and more than one-third ACR70 responses in a heavily refractory population.
The company said the RA data looked especially strong in the JAK- and TNF-refractory subgroup, and management emphasized that the treatment was safe and well-tolerated with no new drug-related safety signals identified.
Roivant expects to use the RA results, along with additional patient-level analysis, to engage FDA on the future development path for IMVT-1402 later this year, including how many registrational studies may ultimately be needed.
For mosliciguat in PH-ILD, management highlighted strong Phase I signals, including roughly 30% average PVR reduction and about 38% peak PVR reduction, with good tolerability and limited systemic side effects.
Roivant said its PH-ILD Phase II study is fully enrolled at 135 patients, the vast majority reached the target dose, and topline data is expected in the second half of 2026; the company also reiterated a strong cash position of $4.3 billion pre-Moderna settlement.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $30.88 on Friday. Roivant Sciences has a fifty-two week low of $10.59 and a fifty-two week high of $32.79. The firm has a market capitalization of $22.10 billion, a PE ratio of -51.47 and a beta of 1.14. The stock’s 50-day simple moving average is $28.46 and its 200-day simple moving average is $25.02.

Insider Buying and Selling at Roivant Sciences

In other news, CEO Matthew Gline sold 289,774 shares of the firm’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $29.16, for a total transaction of $8,449,809.84. Following the sale, the chief executive officer owned 16,736,116 shares of the company’s stock, valued at approximately $488,025,142.56. This trade represents a 1.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Frank Torti sold 587,390 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $27.51, for a total value of $16,159,098.90. Following the sale, the insider directly owned 13,736,547 shares in the company, valued at $377,892,407.97. This trade represents a 4.10% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 1,332,563 shares of company stock worth $37,759,555. 10.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Roivant Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in ROIV. Morgan Stanley raised its position in shares of Roivant Sciences by 31.7% during the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after acquiring an additional 14,036,696 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its stake in Roivant Sciences by 47.6% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 10,677,894 shares of the company’s stock worth $231,710,000 after buying an additional 3,445,511 shares during the last quarter. Perceptive Advisors LLC purchased a new position in Roivant Sciences during the 2nd quarter worth approximately $37,546,000. Marshall Wace LLP grew its stake in Roivant Sciences by 316.5% during the 3rd quarter. Marshall Wace LLP now owns 3,978,001 shares of the company’s stock worth $60,187,000 after buying an additional 3,022,851 shares during the last quarter. Finally, Orbimed Advisors LLC purchased a new position in Roivant Sciences during the 2nd quarter worth approximately $31,324,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

ROIV has been the topic of a number of analyst reports. Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Roivant Sciences in a research report on Friday, May 8th. TD Cowen increased their price target on Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 price target on shares of Roivant Sciences in a research report on Thursday. Finally, Guggenheim increased their price target on Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $33.05.

View Our Latest Stock Analysis on Roivant Sciences

About Roivant Sciences

(Get Free Report)

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.